investors
With a rapidly growing business in Europe and plans for a future launch in the US, Sedana Medical is well-positioned for the future.
We are well on the way to our vision of making inhaled sedation a standard therapy in critical care.
- Mikael Haag
-
CFO AND HEAD OF INVESTOR RELATIONS
- ir@sedanamedical.com
The Share
Press Releases
2026
2026-08-31 07:30
Sedana Medical AB (publ) today announced that the U.S. Food and Drug Administration (FDA) has set April 16, 2027 as the target action date under the Prescription...
2026-08-19 07:30
Sedana Medical AB (publ) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of the company's New Drug Application...
2026-07-17 07:00
NDA submission and improved EBITDA Second quarter 2026 January-June 2026 CEO comments NDA submission and improved EBITDA We submitted our New Drug Application...
Financial Reports
Financial Calendar
Latest Presentation
No presentations found.
